Expected Moves

Market reaction to the Q4 2026 financial results, testing the sustainability of recent +103% YoY net income growth.

Anticipated Ministry of Health, Labour and Welfare (MHLW) announcements regarding biennial National Health Insurance (NHI) drug price revisions.

First comprehensive look at margins and revenue run-rate following the implementation of early 2027 pricing revisions.

Expected summer R&D update detailing late-stage clinical progress and new generic drug application milestones.